Abstract: Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), Tourette's Syndrome, and neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder).
Type:
Grant
Filed:
June 15, 2001
Date of Patent:
May 11, 2004
Assignee:
University of South Florida
Inventors:
Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
Abstract: The present invention relating to a herbal antiallergic composition which comprises a synergistic mixture of extracts from the fruits of Terminalia chebula, bark of Albizia lebbeck, Terminalia bellerica and Emblica officinalis. The present invention also contains the fruits of Piper longum, Piper nigrum and of rhizomes of Zingiber officinale and thoroughly mixed to get the final composition which has potent antiallergic activity. The invention also relates to a process for the preparation of such composition. The composition is particularly useful for the treatment of allergic conditions.
Abstract: The present invention relates to the treatment of depression and/or anxiety by the administration of a combination of a specific class of NK-1 receptor antagonists and an antidepressant or anti-anxiety agent.
Type:
Grant
Filed:
October 16, 2001
Date of Patent:
November 18, 2003
Assignee:
Merck Sharp & Dohme Ltd.
Inventors:
Emma Joanne Carlson, Nadia Melanie Rupniak
Abstract: Described herein is a method for potentiating the action of a serotonin reuptake inhibitor in increasing the availability of serotonin, norepinephrin and dopamine in the brain, by administering to a patient an effective amount of a compound of the formula
wherein
Ar′ is a mono or bicyclic aryl or heteroaryl radical substituted with one to three substituents selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo;
R1 is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio;
R2 is phenyl, naphthyl or (C3-C12)cycloalkyl substituted with one or two substituents selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo;
R3 is selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C
Abstract: A method and solution for perioperatively inhibiting a variety of pain and inflammation processes at wounds from general surgical procedures including oral/dental procedures. The solution preferably includes multiple pain and inflammation inhibitory at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for preemptive inhibition of pain and while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents.
Type:
Grant
Filed:
July 12, 2002
Date of Patent:
November 11, 2003
Assignee:
Omeros Corporation
Inventors:
Gregory A. Demopulos, Pamela A. Pierce, Jeffrey M. Herz
Abstract: Methods for treating humans suffering from, migraine headaches by inhibiting reuptake of norepinephrine are disclosed. The methods comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine.
Type:
Grant
Filed:
January 4, 2002
Date of Patent:
November 4, 2003
Assignee:
Pharmacia & Upjohn Company
Inventors:
Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor
Abstract: The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.
Abstract: Administration of &bgr;-lactam compounds including &bgr;-lactam antibiotics and &bgr;-lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and anti-aggressive behavior modification and enhanced cognition. Therapeutic methods for using such compounds and their pharmaceutical formulations are described.
Abstract: This application relates to methods for treating humans suffering from, fibromyalgia or other somatoform disorders where inhibiting reuptake of norepinephrine is a benefit. The methods comprise a compound having a pharmacological selectivity of serotonin (K1)/norepinephrine (K1) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine.
Type:
Grant
Filed:
January 4, 2002
Date of Patent:
August 26, 2003
Assignee:
Pharmacia & Upjohn Company
Inventors:
Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor
Abstract: This invention relates to an inhibitor having inhibitory activity against neovasculation, cell multiplication, lumen formation and fibroblast growth factor which comprises &bgr;-, &ggr;- or &dgr;-tocotrienol.
Abstract: Methods of use of donepezil having central action for the treatment of function (migraine and primary fibromyalgia) and/or organic (amputation, “phantom limb”, tumoral or traumatic denervation or autoimmune mechanism) central pain syndromes are disclosed.
Abstract: A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human &agr;1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr;1A adrenergic receptor, a human &agr;1B adrenergic receptor, and a human histamine H1 receptor, and, binds to a human &agr;2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr;1C adrenergic receptor. Compounds meeting these criteria are provided.
Type:
Grant
Filed:
November 22, 1999
Date of Patent:
August 5, 2003
Assignee:
Synaptic Pharmaceutical Corporation
Inventors:
Charles Gluchowski, Carlos C. Forray, George Chiu, Theresa A. Branchek, John M. Wetzel, Paul R. Hartig
Abstract: This invention relates to a novel formulation for fat-soluble drugs which self-emulsify in the presence of an aqueous medium with little agitation. More specifically, the invention is concerned with the formulation of a new dosage form for fat-soluble drugs in the form of a soft-gelatin capsule which forms emulsion instantly when the contents are released and mixed with gastrointestinal fluid. The formulation comprises a suitable mixture of drug with an appropriate oil and an appropriate surfactant system.
Type:
Grant
Filed:
July 7, 2000
Date of Patent:
July 22, 2003
Inventors:
David Ho Sue San Ho, Yuen Kah Hay Yuen, Yap Siew Ping Yap
Abstract: The present invention relates to a preventive and/or therapeutic drug for hypercytokinemia, liver diseases, and syndromes caused by the aggravation of sepsis, containing an anti-thrombin agent and/or a thrombin production inhibitor as an active ingredient. The present invention is applicable to prevention of or therapy for diseases such as sepsis, severe sepsis, septic shock, and multiple organ dysfunction syndrome. More particularly, the present invention is useful for an emergency medical service, for treatment of injury caused by a traffic accident, burns, heat attacks, or severe infective diseases. In addition, the present invention is useful for prevention and treatment for hypercytokinemia and liver diseases.
Abstract: A method of producing pharmaceutical compositions using O-desmethyl-N-mono-desmethyl-tramadol for the treatment of pain and various related indications, pharmaceutical compositions containing O-desmethyl-N-mono-desmethyl-tramadol, and a method of treating pain, urinary incontinence, diarrhea or pruritus using O-desmethyl-N-mono-desmethyl-tramadol.
Type:
Grant
Filed:
October 12, 2001
Date of Patent:
July 15, 2003
Assignee:
Gruenenthal GmbH
Inventors:
Babette Koegel, Werner Englberger, Hagen-Heinrich Hennies, Elmar Friderichs
Abstract: Flavones with an isoprenyl group in the 8-position possess very good anti-inflammatory properties and can also be used to treat/prevent/cure skin-disorders when applied in food compositions.
Type:
Grant
Filed:
September 20, 2001
Date of Patent:
July 8, 2003
Assignee:
Lipton, division of Conopco, Inc.
Inventors:
Robert Mark Donovan, Martin Richard Green, Maria Catherine Tasker, Paula Rachel Yates
Abstract: This invention is directed to a method for preventing or treating movement disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II):
wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).
Type:
Grant
Filed:
February 21, 2002
Date of Patent:
July 8, 2003
Assignee:
Ortho-McNeil Pharmaceutical, Inc.
Inventors:
Carlos R. Plata-Salaman, Boyu Zhao, Roy E. Twyman
Abstract: The invention is related to a method of treating chronic hand eczema in a human patient in need of treatment, using oral administration of 9-cis retinoic acid and pharmaceutically acceptable salts and pharmaceutically acceptable hydrolysable esters thereof, in an effective amount of from 0.05 to 1.5 milligrams per kilogram body weight per day.
Abstract: To provide a pharmaceutical composition comprising a macrolide compound, such as tricyclic compound (I) or its pharmaceutically acceptable salt, a dissolution/absorption promoter, a pharmaceutical base, and optionally a compatibilizing agent and/or a thickener. It is satisfactory in stability and absorption kinetics and/or a low irritation potential.